Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐line treatment with abiraterone acetate and prednisone (AA‐...

Full description

Bibliographic Details
Main Authors: Emmy Boerrigter, Guillemette E. Benoist, Inge M. vanOort, Gerald W. Verhaegh, Onno vanHooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter deMol, Tineke J. Smilde, Diederik M. Somford, Niven Mehra, Jack A. Schalken, Nielka P. vanErp
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Molecular Oncology
Subjects:
abiraterone acetate
biomarkers
Castration‐resistant prostate cancer
KLK3
liquid biopsy
RNAs
Online Access:https://doi.org/10.1002/1878-0261.12933

Internet

https://doi.org/10.1002/1878-0261.12933

Similar Items